FDA approval

Class action lawsuit filed against Corcept Therapeutics alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects.

Schall Law Firm launches class action against $ATRA for allegedly concealing manufacturing problems and overstating tabelecleucel prospects in ALLELE study.

Shareholders sue Atara Biotherapeutics for allegedly misleading statements on manufacturing issues and failed ALLELE study data affecting tabelecleucel approval prospects.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

Aquestive Therapeutics faces class action lawsuit alleging securities fraud over false FDA approval statements and concealed anaphylaxis product risks.

Eli Lilly's oral weight loss drug Foundayo met cardiovascular safety goals in Phase 3 trials, showing 57% lower mortality risk versus insulin. FDA filing planned for Q2 2026.

MeiraGTx acquires J&J's bota-vec gene therapy for rare blindness in $25M deal, targeting 2027 launch with promising Phase 3 clinical data.

Immutep gains FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma, with Phase II trial results exceeding efficacy targets by 47%.

Tonix Pharmaceuticals publishes peer-reviewed pharmacokinetic data for TONMYA, the first new fibromyalgia treatment in 15 years, showing rapid absorption and superior bioavailability.

Praxis Precision shares surge 7.15% after FDA accepts essential tremor drug application with January 2027 decision target and positive Phase 3 results.

Schall Law Firm recruits investors for class action against Atara Biotherapeutics over alleged securities fraud involving tabelecleucel drug and ALLELE study claims, covering May 2024-January 2026 purchases.

Amneal launches first two respiratory inhalers, targeting $1.8B combined market opportunity from dedicated Ireland facility.

Law firm Levi & Korsinsky filed class action suit against $CORT alleging fraud regarding relacorilant FDA approval prospects between October 2024 and December 2025.

Schall Law Firm initiates securities fraud class action against uniQure ($QURE) over alleged false FDA approval statements and misleading BLA timelines.

Telix Pharma secures $2.14B partnership with Regeneron for solid tumor radiopharmaceuticals while reporting 11% quarterly revenue growth and FDA acceptance of brain cancer imaging application.

$IDYA's darovasertib-crizotinib combination doubled progression-free survival in metastatic uveal melanoma versus standard care, with FDA submission planned for late 2026.

Securities lawsuit alleges Atara Biotherapeutics concealed manufacturing issues and clinical study deficiencies for tabelecleucel. Investors with $100K+ losses must act before May 22, 2026 deadline.

Class action filed against $CORP alleging securities fraud over misleading statements about relacorilant clinical trials and FDA regulatory prospects.

Milestone Pharmaceuticals launches RESET-PSVT real-world evidence registry for FDA-approved CARDAMYST nasal spray, enrolling 450 patients across 20 sites beginning end of 2026.

FDA accepts Telix's Pixclara NDA for glioma imaging with September 2026 decision target. Orphan Drug designation provides competitive advantages.